Brazilian Federal Agency CAPES Expands Local Re...
AMSTERDAM, March 23 /PRNewswire/ -- Elsevier announced today that the
Brazilian Federal Agency for the
Support and Evaluation of Graduate Education (CAPES) is expanding local
research community access to Scopus(R), the company's flagship product and
the world's largest abstract and citation database of peer-reviewed
literature. CAPES, which assists the Brazilian Ministry of Education in the
formulation of national policies related to post-graduate study, will be
making Scopus available to 200 universities and research institutes in
Brazil, up from 44 in 2007.
"We chose Scopus for its comprehensive and multidisciplinary coverage and
it has exceeded our expectations, becoming an integral part of our mission to
provide the most in-depth and up-to-date global knowledge to the research
community we serve," said CAPES President Professor Jorge Guimaraes. "The
positive feedback we have received has led us to offer the database to
additional universities. The performance measurement capability has also been
very valuable in tracking Brazilian research output and comparing our
progress to other nations."
"We are very pleased that CAPES has chosen to expand the relationship as
it indicates the research community's satisfaction with our database," added
Niels Weertman, Director of Scopus for Elsevier. "We look forward to
continuing to work together to support scientific advancement in Brazil."
About CAPES
Founded in 1951, CAPES assists the Brazilian Ministry of Education in the
formulation of national policies related to post-graduate study. Through
CAPES, the Brazilian government provides a beneficial service to Brazil's
academic community: the Publications Gateway. Created in 2000 by CAPES, the
gateway is one of the greatest bases of scientific information in the world.
Its goal is to reduce regional imbalances by providing free access to quality
scientific and technological information to scientists, professors and
students in 194 universities and research institutes.
About Scopus
Covering the world's research literature, Scopus is the largest abstract
and citation database of peer-reviewed literature and quality Web sources
with smart tools to track analyze and visualize research. Scopus was
designed and developed with over 500 users and librarians internationally.
Its unique database contains abstracts and references from over 15,000
peer-reviewed journals (including more than 200 Brazilian journals) from
4,000 publishers worldwide, ensuring broad interdisciplinary coverage.
In addition, Scopus not only offers users citation information about the
articles covered, but also directly integrates Web and patent searches.
Direct links to full-text articles, library resources and other applications
like reference management software, make Scopus quicker, easier and more
comprehensive to use than any other literature research tool. For more
information about Scopus please visit http://www.info.scopus.com.
About Elsevier
Elsevier is a world-leading publisher of scientific, technical and
medical information products and services. Working in partnership with the
global science and health communities, Elsevier's 7,000 employees in over
70 offices worldwide publish more than 2,000 journals and 1,900 new books
per year, in addition to offering a suite of innovative electronic products,
such as ScienceDirect (http://www.sciencedirect.com/), MD Consult (
http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/),
bibliographic databases, and online reference works.
Elsevier (http://www.elsevier.com/) is a global business headquartered in
Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of
Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-leading
publisher and information provider. Operating in the science and medical,
legal, education and business-to-business sectors, Reed Elsevier provides
high-quality and flexible information solutions to users, with increasing
emphasis on the Internet as a means of delivery. Reed Elsevier's ticker
symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and
ENL (New York Stock Exchange).
CONTACT:
Malkie Bernheim/ Jessica Disch
Padilla Speer Beardsley
+1-212-752-8338
mbernheim@psbpr.com/ jdisch@psbpr.com
AI Summary Disclaimer BETA
The content you are viewing has been generated or assisted by artificial
intelligence (AI). While efforts are made to ensure accuracy and clarity, AI-generated text may
contain inaccuracies, outdated information, or subjective interpretations. This content is intended
for general informational purposes only and should not be considered professional advice or factual
confirmation.
We encourage you to independently verify any information provided,
especially if it will be relied upon for making decisions or taking action. Any reliance you place
on this material is strictly at your own risk. The AI system that produced this content cannot
assess the specifics of individual circumstances, and results may vary based on context and
individual needs.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.
Create an Account
Create your FREE account to receive personalised announcements, watchlists, market updates, investment insights and new features.
Personalise your experience
Tell us a little about yourself to receive personalised content, announcements and relevant investment opportunities.